(163 days)
Not Found
No
The summary focuses on the mechanical and biological aspects of the osseointegrated implant system and explicitly states that the changes are minor and do not modify the intended functionality or fundamental operating principles. There is no mention of AI or ML in the device description, intended use, or performance studies.
Yes
The device is intended to treat hearing loss by amplifying sound and transmitting it to the inner ear, which aligns with the definition of a therapeutic device.
No
Explanation: The provided text describes an auditory osseointegrated implant system that helps patients with hearing loss by amplifying sound and transmitting it to the inner ear via bone conduction. This device is a treatment system, not one used for diagnosis.
No
The device description explicitly states that the system is comprised of three physical parts: a titanium implant, a percutaneous abutment, and a sound processor. This indicates it is a hardware-based medical device, not software-only.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs analyze biological samples: In Vitro Diagnostics are designed to examine specimens taken from the human body (like blood, urine, tissue) to provide information about a person's health.
- This device is an implantable system: The Cochlear Baha system is a surgically implanted device that directly interacts with the patient's skull bone to transmit sound. It does not analyze any biological samples.
- The intended use is for hearing loss: The purpose of this device is to improve hearing in patients with specific types of hearing loss, not to diagnose a condition by analyzing samples.
The description clearly outlines a mechanical and electrical system for sound transmission through bone, which is fundamentally different from the function of an IVD.
N/A
Intended Use / Indications for Use
The Cochlear Baha® auditory osseointegrated implant system using model BA400 abutment is intended for the following patients and indications for use:
- Patients aged 5 and older
- Patients who have a conductive or mixed hearing loss and can still benefit . from sound amplification. The pure tone average bone-conduction hearing threshold (measured at 0.5, 1, 2, and 3kHz) should be better than or equal to 45 dB HL for use with the BP100 sound processor, 55 dB HL for use with the Intenso sound processor, 55 db HL for use with the BP110 Power sound processor, and 65 db HL for use with the Cordelle II Sound Processor.
- Bilateral fitting is intended for patients who meet the above criterion in both . ears, with bilaterally symmetric moderate to severe conductive or mixed hearing loss. Symmetrical bone-conductive thresholds are defined as less than a 10 dB average difference between ears (measured at 0.5, 1, 2, and 3 kHz), or less than a 15dB difference at individual frequencies.
- Patients who suffer from unilateral sensorineural deafness in one ear with . normal hearing in the other ear (i.e. Single-sided deafness: SSD™). Normal hearing is defined as a pure tone average air-conduction hearing threshold (measured at 0.5, 1, 2, and 3 kHz) of better than or equal to 20 ав нг
- Baha for SSD is also indicated for any patient who is indicated for an air-. conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
Product codes (comma separated list FDA assigned to the subject device)
MAH
Device Description
The technology base for the Baha implant was originally derived from the 1952 discovery by Dr. Per-Ingvar Brânemark that titanium was biocompatible with bone, leading to the term "osseointegration". The Brånemark System, as it would later be known, formed the basis for the rapid development and widespread implementation of root form endosseous dental implants, now safely and effectively used by many hundreds of thousands of people worldwide. Root form dental implants share many characteristics with the Baha implant component including material, conformation, and surgical implantation procedures.
The Baha implant system functions by combining 3 parts: a titanium implant, a percutaneous abutment, and a sound processor. The system works by utilizing natural bone transmission as a pathway for sound to travel to the inner ear, bypassing the external auditory canal and middle ear. After surgical placement, the titanium implant naturally integrates with the skull bone over time through a process known as osseointegration. The external sound processor transmits sound vibrations through the percutaneous abutment to the titanium implant. The vibrating implant creates vibrations within the skull that stimulate the nerve fibers of the inner ear, allowing hearing.
The minor changes to this device are only to the abutment, the piece that serves as the connection between the osseointegrated implant and the external sound processor. The changes include a modified design and the addition of a hydroxyapatite coating, neither of which modify the intended functionality or fundamental operating principles of the implant/abutment system.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Ear, Skull bone
Indicated Patient Age Range
5 and older
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing was conducted based on a comparison between proposed and predicate implant/abutment systems. The results were equal or better than established acceptance criteria, where predicate testing was used as a baseline.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 874.3302 Bone-conduction hearing aid.
(a)
Identification. A bone-conduction hearing aid is a wearable sound-amplifying device intended to compensate for impaired hearing and that conducts sound to the inner ear through the skull. The non-implantable components of a bone-conduction hearing aid, such as the external sound processor, are subject to the requirements in § 801.422 of this chapter.(b)
Classification. Class II.
0
OCT 1 2 2012
Cochlear™
Hear now. And abouts
6. 510(k) Summary A. Submitter Information
Submitted by:
On behalf of:
Contact:
B. Date Prepared
். Device Class
D. Device Name Trade/Proprietary Name: Common/Usual Name: Classification Name:
Classification Panel: Product Code:
E. Predicate Device: Trade/Proprietary Name: Common/Usual Name: Classification Name:
Classification Panel: Product Code: 510(k):
Cochlear Americas 13059 East Peakview Ave. Centennial, CO 80111
Cochlear Bone Anchored Solutions AB Konstruktionsvägen 14 SE-435 33 Mölnlycke Sweden (Establishment Number 9616024)
Sean Bundy Director of Quality and Regulatory Cochlear Americas sbundy@cochlear.com (303) 524-7139 (o) (303) 524-6825 (f)
1-May-2012
ll
Cochlear™ Baha® Implant System Auditory Osseointegrated Implant Hearing Aid, Bone Conduction, Implanted 21 CFR 874.3300, Class II Ear Nose and Throat MAH
Cochlear™ Baha® Implant System Auditory Osseointegrated Implant Bone Conduction Hearing Aid 21 CFR 874.3300, Class II Ear Nose and Throat гхв K100360
1
Cochlear™
Hear now. And abuays
F. Purpose of Submission
The Baha implant system works by combining an external sound processor with an abutment and a small titanium implant placed in the skull behind the ear through a simple surgical procedure. The purpose of this Traditional 510(k) is to introduce slight modifications to the BA300 abutment (part of The Cochlear Baha BIA300 Series Implant System) cleared under 510(k) K100360. The modified abutment will be known as model BA400, and the system containing the abutment will be known as the 400 series. The other two parts that make the system function, the implant and the sound processors, will remain unchanged from what is legally cleared. The BA400 will be available as a standalone part or pre-mounted onto a Baha B1300 series titanium implant.
G. Device Description
The technology base for the Baha implant was originally derived from the 1952 discovery by Dr. Per-Ingvar Brânemark that titanium was biocompatible with bone, leading to the term "osseointegration". The Brånemark System, as it would later be known, formed the basis for the rapid development and widespread implementation of root form endosseous dental implants, now safely and effectively used by many hundreds of thousands of people worldwide. Root form dental implants share many characteristics with the Baha implant component including material, conformation, and surgical implantation procedures.
The Baha implant system functions by combining 3 parts: a titanium implant, a percutaneous abutment, and a sound processor. The system works by utilizing natural bone transmission as a pathway for sound to travel to the inner ear, bypassing the external auditory canal and middle ear. After surgical placement, the titanium implant naturally integrates with the skull bone over time through a process known as osseointegration. The external sound processor transmits sound vibrations through the percutaneous abutment to the titanium implant. The vibrating implant creates vibrations within the skull that stimulate the nerve fibers of the inner ear, allowing hearing.
17 of 317
2
Hear now, And always
The minor changes to this device are only to the abutment, the piece that serves as the connection between the osseointegrated implant and the external sound processor. The changes include a modified design and the addition of a hydroxyapatite coating, neither of which modify the intended functionality or fundamental operating principles of the implant/abutment system.
H. Intended Use
The Baha implant system is intended for treatment of patients who have conductive or mixed hearing loss as a result of certain medical conditions such as bilateral atresia and chronic supportive otitis media, and for those who have Single-Sided Deafness (SSD) caused by a congenital condition, surgery, trauma, or disease. The intended use of the system is to provide an osseointegrated fixation point for connection of an external sound processor. The abutment piece, the subject of this 510(k), is intended to provide a connection between the osseointegrated implant and the external sound processor. The intended use remains unchanged from the predicate device.
l. Technological Characteristics
The Baha implant system with the hydroxyapatite coated abutment has the same intended use, the same basic mechanical design, the same functional characteristics, the same fundamental operating principles, and is made of the same titanium as the predicate device.
J. Materials
Titanium according to ASTM F 67-06 Grade 4 USN R50700 (ISO 5832-2)
Hydroxyapatite: Cas(PO4)3(OH) according to ISO 13779-2
K. Performance Data
Performance testing was conducted based on a comparison between proposed and predicate implant/abutment systems. The results were equal or better than established acceptance criteria, where predicate testing was used as a baseline.
3
Image /page/3/Picture/0 description: The image shows the Cochlear company logo. The logo consists of a stylized graphic above the word "Cochlear" in a sans-serif font. The graphic appears to be an abstract representation of a cochlea, the spiral-shaped part of the inner ear. The letters "TM" are written in superscript to the right of the company name.
Hear now. And always
Conclusion L.
Based on the indications for use, technological characteristics, and substantial equivalence comparison to the predicate device, the Baha Implant system with the hydroxyapatite coated abutments has been shown to be safe and effective for its intended use.
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the seal for the Department of Health & Human Services - USA. The seal is circular and contains an image of an eagle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the eagle.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
OCT 12 2012
Cochlear Americas c/o Mr. Sean Bundy Director of Regulatory Affairs and Quality 13059 East Peakview Avenue Centennial, CO 80111
Re: K121317
Trade/Device Name: Cochlear Baha Implant System – BA400 Abutment Regulation Number: 21 CFR 874.3300 Regulation Name: Hearing Aid Regulatory Class: Class II Product Code: MAH Dated: September 21, 2012 Received: September 24, 2012
Dear Mr. Bundy:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
5
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Eun. R. Atkinson, MD
Malvina B. Eydelman, M.D. Director Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Image /page/6/Picture/0 description: The image shows a black and white drawing of a circular object. The object appears to be a ball of yarn or a similar tangled mass of string. The drawing is simple, with rough lines and shading to indicate the texture and form of the object.
Hear now And always
5. Indications for Use Statement
510(k) Number (if known): 1121317
Device Name: Cochlear ™ Baha® BA400 Abutment
Indications for Use:
The Cochlear Baha® auditory osseointegrated implant system using model BA400 abutment is intended for the following patients and indications for use:
- Patients aged 5 and older
- Patients who have a conductive or mixed hearing loss and can still benefit . from sound amplification. The pure tone average bone-conduction hearing threshold (measured at 0.5, 1, 2, and 3kHz) should be better than or equal to 45 dB HL for use with the BP100 sound processor, 55 dB HL for use with the Intenso sound processor, 55 db HL for use with the BP110 Power sound processor, and 65 db HL for use with the Cordelle II Sound Processor.
- Bilateral fitting is intended for patients who meet the above criterion in both . ears, with bilaterally symmetric moderate to severe conductive or mixed hearing loss. Symmetrical bone-conductive thresholds are defined as less than a 10 dB average difference between ears (measured at 0.5, 1, 2, and 3 kHz), or less than a 15dB difference at individual frequencies.
- Patients who suffer from unilateral sensorineural deafness in one ear with . normal hearing in the other ear (i.e. Single-sided deafness: SSD™). Normal hearing is defined as a pure tone average air-conduction hearing threshold (measured at 0.5, 1, 2, and 3 kHz) of better than or equal to 20 ав нг
- Baha for SSD is also indicated for any patient who is indicated for an air-. conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
AND/OR Over-The-Counter Use Prescription Use (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Daviel Cluffn
(Division Sign-Off) Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices
121317
15 of 317
510(k) Number